PATENT CLAIM ANALYSIS

Application Number: 16192162
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-05
Patent Classification: ["546", "273400"]

Abstract:
Novel benzimidazole enantiomeric derivatives, their process of preparation and their therapeutical uses as dual H1 and H4 receptor ligands are disclosed.

Claim (Index 12):
The compound of  claim 1  which is the monohydrate hydrochloride (form II) of (S)-2-[(1H-benzimidazol-2-yl)(1-methylpiperidin-4-yloxy)methyl]-6-fluorophenol, characterized by the following X-ray powder diffraction peaks: (characteristic peaks, 2\u03b8 in \u00b0): 6.3, 13.7, 15.1, 15.7, 16.4, 20.3, 22.1, 24.4, and 29.1.

Metadata:
- Claim Count in Document: 26.0
- Percentile: 98.0
- Lexical Diversity: 1.09524
- Patent Class: 546.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['13825989', '14317024', '13910651', '10582564', '14058164']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7769949082655806
- 35 USC 102 Novelty (BERT): 0.5451164091785867
- Combined Prediction Score: 0.7538070583568812
- Mean Citation Score: 322.902672
- Max Citation Score: 392.15402
- Similarity Product: 281.41766726812125

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test